ISPOR’s COMMITMENT TO GLOBAL INCLUSIVITY AND SCIENTIFIC EXCELLENCE

Published Mar 2, 2017
ANNOUNCEMENT

Princeton, NJ—March 2, 2017—“Science has no geographic boundaries,” said Nancy S. Berg, CEO and Executive Director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). “Scientific research and development is the basis for the rapid globalization of the ISPOR organization and its ongoing and strategic commitment to diverse stakeholder engagement. Scientific excellence and global inclusivity are key components of our organizational values, and of the global enterprise that our Society continues to reflect, encouraging and stimulating a culture of diverse scientific exchange.”

Berg posted these remarks following discussions on the impact of changing political landscapes, including possible travel restrictions as the Society prepares to host its major international meetings on health economics and outcomes research (HEOR) in countries in Asia, Europe, Latin America, and North America. As a scientific and educational society, ISPOR does not take positions on political issues; however, the Society strongly supports open scientific exchange within the global HEOR community, and views efforts to restrict such exchanges as impediments to its mission. ISPOR represents and serves a diverse global, multi-stakeholder audience of more than 20,000 individual and chapter members from 114 countries. The Society’s two MEDLINE®-indexed journals, Value in Health and Value in Health Regional Issues, publish studies from authors who span the globe. In addition, the members who serve in leadership roles for the Society, including the Board of Directors, editorial boards, conference chairs and committees, councils, roundtables, regional consortia and networks, chapters, task forces, and special interest groups represent perspectives from virtually every corner of the world. To foster this level of diversity and inclusion, ISPOR has established a number of initiatives that encourage and facilitate participation, including conference travel grants for attendees outside of North America and Western Europe, scientific awards that recognize researchers and authors worldwide, and membership fee waivers for individuals in low-income countries. It is through such initiatives and the ongoing support of its global network of consortia, networks, and chapters that ISPOR achieves its mission of promoting health economics and outcomes research excellence to improve decision making for health globally.

###

 

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×